NCT00353210 The Derivation of Human Embryonic Stem Cell Lines From PGD Embryos
| NCT ID | NCT00353210 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hadassah Medical Organization |
| Condition | Infertility |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2004-04-06 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2004-04-06 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Human embryonic stem cells (hESCs) are isolated from the early human embryo and have the capability to proliferate indefinitely in culture and to develop into nearly every cell of the human body. hESC are important for studying developmental biology and for cell replacement therapies for the treatment of degenerative human diseases. An additional use for embryonic stem cells would be for the in vitro study of diseases. hESC lines derived from embryos diagnosed as abnormal by PGD testing would afford such models for study. Because embryos tested by PGD and found to be abnormal would only under rare circumstances be transferred to the uterus of a woman (and in most cases would be discarded), the derivation of new hESC lines from these embryos would provide a viable less ethically-objectionable source of cells with which to study the mechanisms of differentiation and developmental biology.
Eligibility Criteria
Inclusion Criteria: * Couple has derived embryos by IVF. * Couple has tested these embryos by PGD and does not want to utilize the embryos to build their families. * Couple signs informed consent. Exclusion Criteria: * Couple does not sign informed consent.
Contact & Investigator
Benjamin E. Reubinoff, M.D. PhD.
PRINCIPAL INVESTIGATOR
Hadassah Medical Organization
Frequently Asked Questions
Who can join the NCT00353210 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00353210 currently recruiting?
Yes, NCT00353210 is actively recruiting participants. Contact the research team at reubinof@md.huji.ac.il for enrollment information.
Where is the NCT00353210 trial being conducted?
This trial is being conducted at Jerusalem, Israel.
Who is sponsoring the NCT00353210 clinical trial?
NCT00353210 is sponsored by Hadassah Medical Organization. The principal investigator is Benjamin E. Reubinoff, M.D. PhD. at Hadassah Medical Organization. The trial plans to enroll 70 participants.